US 7,589,116 B2
Biaryl substituted pyrazoles as sodium channel blockers
Prasun K. Chakravarty, Edison, N.J. (US); Michael H. Fisher, Ringoes, N.J. (US); Jeffrey M. Fisher, legal representative; William H. Parsons, Belle Mead, N.J. (US); Sriram Tyagarajan, Edison, N.J. (US); and Bishan Zhou, Edison, N.J. (US)
Assigned to Merck & Co. Inc., Rahway, N.J. (US)
Appl. No. 10/552,024
PCT Filed Mar. 30, 2004, PCT No. PCT/US2004/009713
§ 371(c)(1), (2), (4) Date Oct. 03, 2005,
PCT Pub. No. WO2004/092140, PCT Pub. Date Oct. 28, 2004.
Claims priority of provisional application 60/460106, filed on Apr. 03, 2003.
Prior Publication US 2006/0183785 A1, Aug. 17, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/415 (2006.01); C07D 231/00 (2006.01)
U.S. Cl. 514—403  [548/356.1] 31 Claims
 
1. A compound represented by Formula (I), (II), (III) or (IV):

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, wherein
HET is one of the following heterocycles:

OG Complex Work Unit Drawing
R1 is
(a) H;
(b) C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, or C1-C4-alkyl-[C3-C6-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2—(C1-C4)alkyl, O—CONRaRb, NRaRb, N(Ra)CONRaRb, COO—(C1-C4)alkyl, COOH, CN, CONRaRb, SO2NRaRb, N(Ra)SO2NRaRb, —C(═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(c) —O—C1-C6-alkyl, —O—C3-C6-cycloalkyl, —S—C1-C6-alkyl or —S—C3-C6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2—(C1-C4)alkyl, O—CONRaRb, NRaRb, N(Ra)CONRaRb, COO—(C1-C4)alkyl, COOH, CN, CONRaRb, SO2NRaRb, N(Ra)SO2NRaRb, —C (═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(d) —C0-C4-alkyl-C1-C4-perfluoroalkyl, or —O—C0-C4-alkyl-C1-C4-perfluoroalkyl;
(e) —OH;
(f) —O-aryl, or —O—C1-C4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO —ORa, viii) —C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C—;
(g) —OCON(Ra)(Rb), or —OSO2N(Ra)(Rb);
(h) —SH, or —SCON(Ra)(Rb);
(i) NO2;
(j) NRaRb, —N(CORa)Rb, —N(SO2Ra)Rb, —N(Ra)SO2N(Ra)2, —N(ORa)CONRaRb, —N(Ra)SO2Ra or —N(Ra)CON(Ra)2;
(k) —CH(ORa)Ra, —C(ORb)CF3, —CH(NHRb)Ra, —C(═O)Ra, C(═O)CF3, —SOCH3, —SO2CH3, COORa, CN, CONRaRb, —COCONRaRb, —SO2NRaRb, —CH2O—SO2NRaRb, SO2N(Ra)ORa, —C(═NH)NH2, —CRa═N—ORa, CH═CHCONRaRb;
(l) —CONRa(CH2)0-2C(Ra)(Rb)(CH2)0-2CONRaRb;
(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)Ra, v) C1-C6-alkyl, vi) —O—Ra, vii) —NRaRb, viii) —C0-C4-alkyl-CO—ORa, ix) —(C0-C4-alkyl) -NH—CO—ORa, x) —(C0-C4-alkyl)-CO—NRaRb, xi) —S(O)0-2Ra, xii)—SO2NRaRb, xiii) —NHSO2Ra, xiv) —C1-C4-perfluoroalkyl, and xv) —O—C1-C4-perfluoroalkyl;
(n) —C(Ra)═C(Rb)—COORa, or —C(Ra)═C(Rb)—CONRaRb;
(o)

OG Complex Work Unit Drawing
(p) piperidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) —CN, ii) —C(═O)(Ra), iii) C1-C6-alkyl, iv) —ORa, v) —NRaRb, vi) —C0-C4-alkyl -CO—ORa, vii) —(C0-C4-alkyl)-NH—CO—ORa, viii) —(C0-C4-alkyl)-CON(Ra)(Rb), ix) —SRa, x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra xiii) —C1-C4-perfluoroalkyl and xiv) —O—C1-C4-perfluoroalkyl;
Ra is
(a) H;
(b) C1-C4-alkyl, optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2—(C1-C4)alkyl, —OCONH2, —OCONH(C1-C4alkyl), —OCON(C1-C4alkyl)(C1-C4alkyl), —OCONHC1-C4alkyl-aryl), —OCON(C1-C4alkyl) (C1-C4alkyl-aryl), NH2, NH(C1-C4alkyl), N(C1-C4alkyl)(C1-C4alkyl), NH(C1-C4alkyl-aryl), N(C1-C4alkyl)(C1-C4alkyl-aryl), NHCONH2, NHCONH(C1-C4alkyl), NHCONH(C1-C4alkyl-aryl), —NHCON(C1-C4alkyl)(C1-C4alkyl), NHCON (C1-C4alkyl)(C1-C4alkyl-aryl), N(C1-C4alkyl)CON(C1-C4alkyl)(C1-C4alkyl), N(C1-C4alkyl)CON(C1-C4alkyl)(C1-C4alkyl-aryl), COO—(C1-C4-alkyl), COOH, CN, CONH2, CONH(C1-C4alkyl), CON(C1-C4alkyl)(C1-C4alkyl), SO2NH2, SO2NH (C1-C4alkyl), SO2NH(C1-C4alkyl-aryl), SO2N(C1-C4alkyl)(C1-C4alkyl), NHSO2NH2, —C(═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(c) C0-C4-alkyl-(C1-C4)-perfluoroalkyl; or
(d) —C1-C4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(C1-C4-alkyl), v) —O(C1-C4-alkyl), vi) —N(C1-C4-alkyl)(C1-C4-alkyl), vii) —C1-10alkyl, and viii) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C—;
Rb is
(a) H; or
(b) C1-C6-alkyl, optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2—(C1-C4)alkyl, —OCONH2, —OCONH(C1-C4alkyl), NH2, NH(C1-C4alkyl), N(C1-C4alkyl)(C1-C4alkyl), NHCONH2, NHCONH (C1-C4alkyl), —NHCON(C1-C4alkyl)(C1-C4alkyl), COO—(C1-C4-alkyl), COOH, CN, or CONH2;
R2 is:
(a) H;
(b) —C1-C4-alkyl, —C3-C6-cycloalkyl or —C1-C4-alkyl-(C3-C6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2—(C1-C4)alkyl, O—CONRaRb, NRaRb, N(Ra)CONRaRb, COO—(C1-C4)alkyl, COOH, CN, CONRaRb, SO2NRaRb, N(Ra)SO2NRaRb, —C(═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(c) —C0-C4-alkyl-C1-C4-perfluoroalkyl;
(d) aryl or —(C1-C4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —(C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C (O)—, —CH(OH)—, —C═C—, or —C≡C—;
(e) —C(═O)(Ra), —CONRaRb, COO—C1-C4)alkyl, —SO2Ra, N(Ra)CORa, —SO2N(Ra)(Rb);
R3 is
(a) H;
(b) —C1-C4-alkyl, —C3-C6-cycloalkyl or —C1-C4-alkyl-(C3-C6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, S(O)0-2-(C1-C4)alkyl, O—CONRaRb, NRaRb, N(Ra)CONRaRb, COO—(C1-C4)alkyl, COOH, CN, CONRaRb, SO2NRaRb, N(Ra)SO2NRaRb, —C(═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(c) —C0-C4-alkyl-C1-C4-perfluoroalkyl;
(d) aryl or —(C1-C4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —(C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C—;
(e) —O—C1-C4-alkyl, —O—C0-C4-alkyl-C1-C4-perfluoroalkyl, —O-aryl or —O(C1-C4-alkyl)-aryl;
(f) —C(═O)(Ra), —SO2Ra, —SO2N(Ra)(Rb), CN, NRaRb, NO2, F, Cl, Br, I, OH, OCONRaRb, O(C1-C4-alkyl)CONRaRb, —OSO2NRaRb, COORa, N(Ra)CORa, or CONRaRb;
R4 and R5 each independently is:
(a) H;
(b) —C1-C6-alkyl, —C2-C6-alkenyl, —C2-C6-alkynyl or —C3-C6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF3, —O—(C1-C4)alkyl, CN, —N(Ra)(Rb), —N(Ra)CO—(C1-C4)alkyl, COORb, CON(Ra)(Rb) or phenyl;
(c) —O—C0-C6-alkyl, —O-aryl, or —O—C1-C4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —(C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C—;
(d) —C0-C4-alkyl-C1-C4-perfluoroalkyl, or —O—C0-C4-alkyl-C1-C4-perfluoroalkyl; or
(e) CN, NH2, NO2, F, Cl, Br, I, OH, OCON(Ra)(Rb)O(C1-C4-alkyl)CONRaRb, —OSO2N(Ra)(Rb), COORb, CON(Ra)(Rb), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —(C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)—CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C; and
R6, R7 and R8 each independently is:
(a) H;
(b) C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl or C3-C6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, OCON(Ra)(Rb), NRaRb, COORa, CN, CONRaRb, N(Ra)CONRaRb, N(Ra)SO2NRaRb, SO2NRaRb, S(O)0-2(C1-C4-alkyl), —C(═NH)NH2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;
(c) —O—C1-C6-alkyl, —O—C3-C6-cycloalkyl, —S—C1-C6-alkyl or —S—C3-C6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF3, OH, O—(C1-C4)alkyl, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, COOH, CN, CONH2, CONH(C1-C4-alkyl), CONH(C1-C4-alkyl)2, SO2NH2, SO2NH(C1-C4-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;
(d) —C0-C4-alkyl-C1-C4-perfluoroalkyl, or —O—C0-C4-alkyl-C1-C4-perfluoroalkyl;
(e) —O-aryl, or —O—C1-C4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C; (f) CN, N(Ra)(Rb), NO2, F, Cl, Br, I, —ORa, —SRa, —OCON(Ra)(Rb), —OSO2N(Ra)(Rb), COORb, CON(Ra)(Rb), —N(Ra)CON(Ra)(Rb), —N(Ra)SO2N(Ra)(Rb), C(ORb)Ra, —C(ORa)CF3, C(NHRa)CF3, C(═O)Ra, C(═O)CF3, —SOCH3, —SO2CH3, —NHSO2(C1-6-alkyl), —NHSO2-aryl, SO2N(Ra)(Rb), —CH2OSO2N(Ra)(Rb), SO2N(Rb)—ORa, —C(═NH)NH2, —CRa═N—ORa, CH═CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) —CN, iii) —NO2, iv) —C(═O)(Ra), v) —ORa, vi) —NRaRb, vii) —C0-4alkyl-CO—ORa, viii) —(C0-4alkyl)-NH—CO—ORa, ix) —(C0-4alkyl)-CO—N(Ra)(Rb), x) —S(O)0-2Ra, xi) —SO2N(Ra)(Rb), xii) —NRaSO2Ra, xiii) —C1-10alkyl, and xiv) —C1-10alkyl, wherein one or more of the alkyl carbons can be replaced by a —NRa—, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(Ra)—, —N(Ra)—C(O)—, —N(Ra)—C(O)—N(Ra)—, —C(O)—, —CH(OH)—, —C═C—, or —C≡C; or when R6 and R7 are present on adjacent carbon atoms, R6 and R7, together with the ring to which they are attached, may form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any aromatic ring of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) —CN, iii) —NO2, iv) —CHO, v) —O—C1-4alkyl, vi) —N(C 0-4alkyl)(C0-4alkyl), vii) —C0-4alkyl-CO—O(C0-4alkyl), viii) —(C0-4alkyl)-NH—CO—O(C0-4alkyl), ix) —(C0-4alkyl)-CO—N(C0-4alkyl)(C0-4alkyl), x) —S(C0-4alkyl), xi) —S(O)(C1-4alkyl), xii) —SO2(C0-4alkyl), xiii) —SO2N(C0-4alkyl)(C0-4alkyl), xiv) —NHSO2(C0-4alkyl)(C0-4alkyl), xv) —C1-10alkyl and xvi) —C1-10alkyl in which one or more of the carbons can be replaced by a —N(C0-6alkyl)-, —O—, —S(O)1-2—, —O—C(O)—, —C(O)—O—, —C(O)—N(C0-6alkyl)-, —N(C0-6alkyl)-C(O)—, —N(C0-6alkyl)-C(O)—N(C0-6alkyl)-, —C(O)—, —CH(OH), —C═C—, or —C≡C—; with the proviso that R1, R3 and R6 are Not hydrogen at the same time.